Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Gain Therapeutics (GANX) EBITDA Margin (2020 - 2023)

Gain Therapeutics (GANX) has 4 years of EBITDA Margin data on record, last reported at 9477.68% in Q1 2023.

  • For Q1 2023, EBITDA Margin fell 217093.0% year-over-year to 9477.68%; the TTM value through Dec 2023 reached 40328.26%, down 2764016.0%, while the annual FY2023 figure was 40328.26%, 2692578.0% down from the prior year.
  • EBITDA Margin reached 9477.68% in Q1 2023 per GANX's latest filing, down from 5442.98% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 4603.35% in Q2 2021 and bottomed at 46819.42% in Q1 2021.
  • Average EBITDA Margin over 4 years is 15913.42%, with a median of 9477.68% recorded in 2023.
  • Peak YoY movement for EBITDA Margin: crashed -3914281bps in 2021, then soared 3951266bps in 2022.
  • A 4-year view of EBITDA Margin shows it stood at 17680.4% in 2020, then plummeted by -49bps to 26427.02% in 2021, then skyrocketed by 79bps to 5442.98% in 2022, then plummeted by -74bps to 9477.68% in 2023.
  • Per Business Quant database, its latest 3 readings for EBITDA Margin were 9477.68% in Q1 2023, 5442.98% in Q2 2022, and 7306.75% in Q1 2022.